Pancreas Resection for Colorectal Metastasis: Retrospective Study

Sponsor
Ospedale Generale Di Zona Moriggia-Pelascini (Other)
Overall Status
Recruiting
CT.gov ID
NCT05714475
Collaborator
(none)
15
1
5.9
2.5

Study Details

Study Description

Brief Summary

The aim of this study is to collect data from different centres to obtain a larger case series and enable a better definition of the outcomes after pancreatic metastasectomy from primary colorectal cancer. To evaluate the possible benefits of surgery, we intend to retrospectively analyze the outcome of patients in whom pancreatic metastases have been surgically treated.

Primary objective;

  1. To evaluate feasibility and safety of pancreas resection in metastatic colorectal cancer

  2. To evaluate oncological outcome at six months from surgical procedure

Secondary objective:
  1. To evaluate oncological outcome at 12 months from surgical procedure
Condition or Disease Intervention/Treatment Phase
  • Procedure: Pancreas surgery

Detailed Description

Metastases to the Pancreas are quite rare and account for less than 5% of pancreatic malignancies diagnosed in living patients.

In autopsy cases of malignant tumours, the incidence of pancreatic secondary tumours reaches 15%.

The metastases are predominantly of epithelial origin, most commonly from lung, stomach, small bowel, colon-rectum, kidney , breast , liver , ovary ,melanoma and urinary bladder.

It is largely described that resection of isolated metastasis to the lung or liver from primary tumour leads to improved survival; yet there is no consensus about the benefit of pancreas resection for metastases and the gold standard treatment is still not well defined.

The lack of data for pancreas metastases resections depends on low incidence and high perioperative risks. However, the improvement in morbidity and mortality rates after pancreaticoduodenectomy made the indication for this operation acceptable.

One of the larger series concluded that an aggressive surgical approach might be warranted if the patient can be rendered free of disease.

The majority of case series referred to renal cell carcinoma and resection for CCR are episodic. However there are several reports of solitary resected pancreatic metastases from colorectal cancer There is currently very limited experience with the surgical resection of isolated pancreatic colorectal metastases, and the role of surgery in the management of these patients is still debated.

To date, no prospective randomized or case-controlled studies have been performed to evaluate the role of surgical resection. Additionally, many of the existing retrospective studies are limited because of the small number of patients who were treated during prolonged periods of time.

Aim of the study The aim of this study is to collect data from different centres to obtain a larger case series and enable a better definition of the outcomes after pancreatic metastasectomy from primary colorectal cancer. To evaluate the possible benefits of surgery, the investigators intend to retrospectively analyze the outcome of patients in whom pancreatic metastases have been surgically treated.

The investigators launched the study aiming at demonstrating that pancreatic resection for colorectal metastases may be a safe and feasible procedure in selected patients and may provide long-term survival. The investigators sought to address the role of surgical resection and survival benefit from surgery. The investigators suppose to achieve a good prognosis with a median survival close to that observed after resection of hepatic metastases.

The guidelines for the treatment of colorectal cancer recommend resection of hematogenous metastases if they are deemed resectable.

Study design This study is an international multicenter retrospective cohort study to assess the outcomes of patients that underwent pancreas resection for solitary colorectal metastasis.

Aim of surgical interventions is to remove metastases in association to radical lymphadenectomy thus to achieve R0 result.

Patient data will be retrospectively analyzed and demographic characteristics, comorbidity status, clinical and radiological findings, treatment strategies , 30-day morbidity and mortality, oncological outcomes at 6 and 12 months will be evaluated.

Study Design

Study Type:
Observational
Anticipated Enrollment :
15 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Multicentre Retrospective Study on Pancreas Resection for Colorectal Cancer Metastasis
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Mar 31, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Pancreas resection for colorectal metastasis

Patient underwent a pancreas resection (whipple, distal pancreasectomy ...) with inclusion criteria. Criteria Inclusion Criteria: Isolated pancreatic metastases from Colorectal cancer Previous surgery for colorectal cancer Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas Other procedures: total-pancreatectomy distal-pancreatectomy other metastases resection R0 resection no signs of peritoneal metastasis or tumor manifestations outside of the pancreas. CT Scan before surgery Exclusion Criteria: metastases from different malignancies other malignancies surgically unmanageable lesions Multiple synchronous colorectal metastasis

Procedure: Pancreas surgery
Criteria Inclusion Criteria: Isolated pancreatic metastases from Colorectal cancer Previous surgery for colorectal cancer Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas pancreaticoduodenectomy total-pancreatectomy distal-pancreatectomy other metastases resection

Outcome Measures

Primary Outcome Measures

  1. 30-day mortality [30 days]

    assessed by the number of patients with pancreas resection deceased within 30-days from the surgical intervention

  2. 30-day morbidity [30 days]

    assessed by the number of patients with pancreatic resection who experienced any type of postoperative complication within 30-days from the surgical intervention

  3. Overall survival [6 months]

    6 moths survival 3. Survival : 6 moths survival 4. Disease free survival at 6 months

  4. Disease free survival [6 months]

    disease free survival at 6 months

Secondary Outcome Measures

  1. Overall survival (12) [12 months]

    Overall survival at 12 months

  2. Disease free survival (12) [12 months]

    disease free survival at 12 months

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Isolated pancreatic metastases from Colorectal cancer

  • Previous surgery for colorectal cancer

  • Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas

  • Other procedures:

total-pancreatectomy distal-pancreatectomy other metastases resection

  • R0 resection

  • no signs of peritoneal metastasis or tumor manifestations outside of the pancreas.

  • CT Scan before surgery

Exclusion Criteria:
  • metastases from different malignancies

  • other malignancies

  • surgically unmanageable lesions

  • Multiple synchronous colorectal metastasis

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ospedale Generale di zona Moriggia Pelascini Gravedona Como Italy 22015

Sponsors and Collaborators

  • Ospedale Generale Di Zona Moriggia-Pelascini

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Francesco Palmieri, MD, Principal investigator, Ospedale Generale Di Zona Moriggia-Pelascini
ClinicalTrials.gov Identifier:
NCT05714475
Other Study ID Numbers:
  • MP1
First Posted:
Feb 6, 2023
Last Update Posted:
Feb 8, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Francesco Palmieri, MD, Principal investigator, Ospedale Generale Di Zona Moriggia-Pelascini
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2023